G1 Therapeutics CEO and leadership

Jack Bailey is a Corporate Advisor at Eshelman Institute for Innovation, Chief Executive Officer at G1 Therapeutics Inc, and Vice President at ELI LILLY & CO and is based in Chapel Hill, North Carolina. He has worked as Senior VP:US Account Markets at ELI LILLY & CO, Consultant at GSK, and President:US Pharmaceuticals at GSK. Jack works or has worked as BOARD MEMBER at Joint Commission Resources, BOARD MEMBER at Triangle Global Health Consortium Inc, and BOARD MEMBER at National Pharmaceutical Council Executive Committee. He attended Hobart and William Smith Colleges, University of North Carolina at Chapel Hill, and UNC Kenan-Flagler Business School.

Mr. Murdock joined G1 in 2017. In his role as Chief Operating Officer, he is responsible for clinical operations, chemistry, manufacturing and controls (CMC), project management, product development outsourcing, IT, and facilities. Previously, Mr. Murdock served as Vice President and Global Head of the Oncology Center of Excellence at QuintilesIMS (now IQVIA), where he focused on developing insights and innovations that helped improve the probability of success for QuintilesIMS’ oncology customer development projects and programs. Mr. Murdock has more than 20 years of work experience as a successful senior executive in the medical research industry, specializing in oncology, multiple sclerosis and other autoimmune diseases. Prior to QuintilesIMS, Mr. Murdock also held senior positions at Ergomed, Genzyme/Sanofi, ILEX Oncology and US Oncology. Mr. Murdock earned his M.S. in biology and his B.S. in microbiology from the University of Texas, Arlington.

Mr. Avagliano joined G1 as Chief Business Officer in 2019. In this role, he is responsible for leading the company’s global partnering and corporate development strategy and execution. Mr. Avagliano has significant experience in screening, evaluation, financial modeling, due diligence, contract negotiations, and deal closings. Previously, he was Vice President, Corporate Development at Pfizer Inc., where he was responsible for the evaluation, planning and execution of significant corporate level transactions and oversaw the Mergers and

Jack Bailey is a Corporate Advisor at Eshelman Institute for Innovation, Chief Executive Officer at G1 Therapeutics Inc, and Vice President at ELI LILLY & CO and is based in Chapel Hill, North Carolina. He has worked as Senior VP:US Account Markets at ELI LILLY & CO, Consultant at GSK, and President:US Pharmaceuticals at GSK. Jack works or has worked as BOARD MEMBER at Joint Commission Resources, BOARD MEMBER at Triangle Global Health Consortium Inc, and BOARD MEMBER at National Pharmaceutical Council Executive Committee. He attended Hobart and William Smith Colleges, University of North Carolina at Chapel Hill, and UNC Kenan-Flagler Business School.